PT - JOURNAL ARTICLE AU - Bott, Laura C AU - Forouhan, Mitra AU - Lieto, Maria AU - Sala, Ambre J AU - Ellerington, Ruth AU - Johnson, Janel O AU - Speciale, Alfina A AU - Criscuolo, Chiara AU - Filla, Alessandro AU - Chitayat, David AU - Nemeth, Andrea H AU - , AU - Angelucci, Francesco AU - Lim, Wooi Fang AU - Striano, Pasquale AU - Zara, Federico AU - Helbig, Ingo AU - Muona, Mikko AU - Courage, Carolina AU - Lehesjoki, Anna-Elina AU - Berkovic, Samuel F AU - , AU - Fischbeck, Kenneth H AU - Brancati, Francesco AU - Morimoto, Richard I AU - Wood, Matthew JA AU - Rinaldi, Carlo TI - Biallelic and <em>de novo</em> variants in <em>ATP6V0A1</em> cause progressive myoclonus epilepsy and developmental and epileptic encephalopathy AID - 10.1101/2021.06.01.21257500 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.01.21257500 4099 - http://medrxiv.org/content/early/2021/06/07/2021.06.01.21257500.short 4100 - http://medrxiv.org/content/early/2021/06/07/2021.06.01.21257500.full AB - The vacuolar H+-ATPase is a large multi-subunit proton pump, composed of an integral membrane V0 domain, involved in proton translocation, and a peripheral V1 domain, catalysing ATP hydrolysis. This complex is widely distributed on the membrane of various subcellular organelles, such as endosomes and lysosomes, and plays a critical role in cellular processes ranging from autophagy to protein trafficking and endocytosis. Variants in ATP6V0A1, the brain-enriched isoform in the V0 domain, have been recently associated with developmental delay and epilepsy in four individuals. Here we identified 17 individuals from 14 unrelated families with both with new and previously characterised variants in this gene, representing the largest cohort to date. Five affected subjects with biallelic variants in this gene presented with a phenotype of early-onset progressive myoclonus epilepsy with ataxia, while 12 individuals carried de novo missense variants and showed severe developmental and epileptic encephalopathy. The R740Q mutation, which alone accounts for almost 50% of the mutations identified among our cases, leads to failure of lysosomal hydrolysis by directly impairing acidification of the endolysosomal compartment, causing autophagic dysfunction and severe developmental defect in C. elegans. Altogether, our findings further expand the neurological phenotype associated with variants in this gene and provide a direct link with endolysosomal acidification in the pathophysiology of ATP6V0A1-related conditions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAll funding support in the present work is disclosed in the manuscript. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the ethics committee of the following institutes: University of Federico II (Italy), University of L Aquila (Italy), G. Gaslini Institute (Italy), University of Exeter (UK), Nottingham University Hospital (UK), Salpetriere Hospital (France), University of Toronto (Canada), University of Ottawa (Canada), St. Luke s Children's Hospital (USA), Floating Hospital for Children at Tufts Medical Center (USA), Gillette Children s Specialty Healthcare Children's Hospital (USA), Children s Hospital of Philadelphia (USA), Peking University First Hospital, Beijing (China). Written consent for the study was obtained from patients or legal representatives according to the Declaration of Helsinki. When individuals were not contacted directly, de-identified phenotypic and genomic data were used. Patient or guardian consent was given for the publication of the patient s data and clinical information.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials.